IGIV Trials Should Focus On Infections, Use Non-Inferiority Design - FDA
Executive Summary
Clinical trials for intravenous immune globulin products can be "non-inferiority" studies, Center for Biologics Evaluation & Research Hematology Division Deputy Director Basil Golding, MD, told the Blood Products Advisory Committee.